Abstract
Purpose
The surgical outcome on glucose metabolism in acromegaly patients is not fully understood. We aimed to investigate the impact of surgery on glucose metabolism and identify key factors that influence alterations of glucose metabolic status in acromegaly patients.
Methods
Oral glucose tolerance test was performed in 151 newly diagnosed acromegaly patients before and 3–12 months after surgery. Insulin resistance and insulin secretion was assessed. Patients were grouped as cured, discordant, and having active disease according to postoperative growth hormone (GH) and insulin-like growth factor-1 (IGF-1) levels. Receiver-operating characteristic curves were generated to determine the optimal cut-off points to predict the impact of surgery on glucose metabolism.
Results
At baseline, 32.5%, 41.7%, and 25.8% patients were categorized as having normal glucose tolerance (NGT), impaired glucose tolerance (IGT), and diabetes mellitus (DM), respectively. After surgery, improved glucose tolerance was observed in 87.3% patients with IGT and 66.7% patients with DM. Deterioration was observed in 14.3% patients with NGT. Glucose tolerance improved in patients with lower preoperative FBG, 2 h-BG, and HbA1c and higher HOMA-β and IGI/IR. The proportion of NGT was significantly increased in surgically cured patients (28.3% vs. 79.2%, P < 0.001) and those with normal GH but elevated IGF-1 levels (25.6% vs. 79.5%, P < 0.001), but not in patients with active disease (42.9% vs. 57.1%, P = 0.131). Baseline FBG < 6.35 mmol/l predicted improved glucose metabolism after surgery.
Conclusions
Glucose metabolic status improved in patients with preserved β-cell function. Preoperative FBG was an independent predictor for improved glucose tolerance status after surgery.
Similar content being viewed by others
References
J.J. Puder, S. Nilavar, K.D. Post, P.U. Freda, Relationship between disease-related morbidity and biochemical markers of activity in patients with acromegaly. J. Clin. Endocrinol. Metab. 90(4), 1972–1978 (2005)
A. Colao, D. Ferone, P. Marzullo, G. Lombardi, Systemic complications of acromegaly: epidemiology, pathogenesis, and management. Endocr. Rev. 25(1), 102 (2004)
D.R. Clemmons, Roles of insulin-like growth factor-I and growth hormone in mediating insulin resistance in acromegaly. Pituitary 5(3), 181–183 (2002)
L. Katznelson, E.R. Laws Jr., S. Melmed, M.E. Molitch, M.H. Murad, A. Utz, J.A. Wass, S. Endocrine, Acromegaly: an endocrine society clinical practice guideline. J. Clin. Endocrinol. Metab. 99(11), 3933–3951 (2014)
A. Goldhirsch, J.H. Glick, R.D. Gelber, H.J. Senn, A consensus on criteria for cure of acromegaly. J. Clin. Endocrinol. Metab. 95(7), 3141–3148 (2010)
M.L. Jaffrain-Rea, G. Minniti, C. Moroni, V. Esposito, E. Ferretti, A. Santoro, T. Infusino, G. Tamburrano, G. Cantore, R. Cassone, Impact of successful transsphenoidal surgery on cardiovascular risk factors in acromegaly. Eur. J. Endocrinol. 148(2), 193 (2003)
Y. Kinoshita, H. Fujii, A. Takeshita, M. Taguchi, M. Miyakawa, K. Oyama, S. Yamada, Y. Takeuchi, Impaired glucose metabolism in Japanese patients with acromegaly is restored after successful pituitary surgery if pancreatic {beta}-cell function is preserved. Eur. J. Endocrinol. 164(4), 467–473 (2011)
M. Tzanela, D.A. Vassiliadi, N. Gavalas, A. Szabo, E. Margelou, A. Valatsou, C. Vassilopoulos, Glucose homeostasis in patients with acromegaly treated with surgery or somatostatin analogues. Clin. Endocrinol. 75(1), 96 (2011)
A.D. Association, Diagnosis and classification of diabetes mellitus. Diabetes Care 34(Suppl 1), S62–S69 (2011)
A.V. Dreval, I.V. Trigolosova, I.V. Misnikova, Y.A. Kovalyova, R.S. Tishenina, I.S. Barsukov, A.V. Vinogradova, B.H.R. Wolffenbuttel, Prevalence of diabetes mellitus in patients with acromegaly. Endocr. Connect. 3(2), 93–98 (2014)
J. Dal, U. Feldt-Rasmussen, M. Andersen, L.O. Kristensen, P. Laurberg, L. Pedersen, O.M. Dekkers, H.T. Sorensen, J.O. Jorgensen, Acromegaly incidence, prevalence, complications and long-term prognosis: a nationwide cohort study. Eur. J. Endocrinol. 175(3), 181–190 (2016)
W. Yang, J. Lu, J. Weng, W. Jia, L. Ji, J. Xiao, Z. Shan, J. Liu, H. Tian, Q. Ji, Prevalence of diabetes among men and women in China. New Engl. J. Med. 362(25), 2425 (2010)
O. Alexopoulou, M. Bex, P. Kamenicky, A.B. Mvoula, P. Chanson, D. Maiter, Prevalence and risk factors of impaired glucose tolerance and diabetes mellitus at diagnosis of acromegaly: a study in 148 patients. Pituitary 17(1), 81–89 (2014)
S. Fieffe, I. Morange, P. Petrossians, P. Chanson, V. Rohmer, C. Cortet, F. Borson-Chazot, T. Brue, B. Delemer, F.A. Registry, Diabetes in acromegaly, prevalence, risk factors, and evolution: data from the French acromegaly registry. Eur. J. Endocrinol. 164(6), 877 (2011)
S. Kasayama, M. Otsuki, M. Takagi, H. Saito, S. Sumitani, H. Kouhara, M. Koga, Y. Saitoh, T. Ohnishi, N. Arita, Impaired beta-cell function in the presence of reduced insulin sensitivity determines glucose tolerance status in acromegalic patients. Clin. Endocrinol. 52(5), 549–555 (2000)
R. Helseth, S.M. Carlsen, J. Bollerslev, J. Svartberg, M. Øksnes, S. Skeie, S.L. Fougner, Preoperative octreotide therapy and surgery in acromegaly: associations between glucose homeostasis and treatment response. Endocrine 51(2), 298–307 (2016)
A. Colao, R. Attanasio, R. Pivonello, P. Cappabianca, L.M. Cavallo, G. Lasio, A. Lodrini, G. Lombardi, R. Cozzi, Partial surgical removal of growth hormone-secreting pituitary tumors enhances the response to somatostatin analogs in acromegaly. J. Clin. Endocrinol. Metab. 91(1), 85–92 (2006)
A. Colao, R.S. Auriemma, M. Galdiero, P. Cappabianca, L.M. Cavallo, F. Esposito, L.F. Grasso, G. Lombardi, R. Pivonello, Impact of somatostatin analogs versus surgery on glucose metabolism in acromegaly: results of a 5-year observational, open, prospective study. J. Clin. Endocrinol. Metab. 94(2), 528–537 (2009)
C.L. Ronchi, V. Varca, P. Beck-Peccoz, E. Orsi, F. Donadio, A. Baccarelli, C. Giavoli, E. Ferrante, A. Lania, A. Spada, Comparison between six-year therapy with long-acting somatostatin analogs and successful surgery in acromegaly: effects on cardiovascular risk factors. J. Clin. Endocrinol. Metab. 91(1), 121–128 (2006)
N. Møller, O. Schmitz, J.O. Jøorgensen, J. Astrup, J.F. Bak, S.E. Christensen, K.G. Alberti, J. Weeke, Basal- and insulin-stimulated substrate metabolism in patients with active acromegaly before and after adenomectomy. J. Clin. Endocrinol. Metab. 74(5), 1012–1019 (1992)
K. Mori, Y. Iwasaki, Y. Kawasaki-Ogita, S. Honjo, Y. Hamamoto, H. Tatsuoka, K. Fujimoto, H. Ikeda, Y. Wada, Y. Takahashi, Improvement of insulin resistance following transsphenoidal surgery in patients with acromegaly: correlation with serum IGF-I levels. J. Endocrinol. Invest. 36(10), 853–859 (2013)
B. Gallwitz, C. Kazda, P. Kraus, C. Nicolay, G. Schernthaner, Contribution of insulin deficiency and insulin resistance to the development of type 2 diabetes: nature of early stage diabetes. Acta Diabetol. 50(1), 39–45 (2013)
M. Stelmachowskabanaś, G. Zieliński, P. Zdunowski, J. Podgórski, W. Zgliczyński, The impact of transsphenoidal surgery on glucose homeostasis and insulin resistance in acromegaly. Neurol. Neurochir. Pol. 45(4), 328–334 (2011)
A.L. Espinosa-De-Los-Monteros, B. González, G. Vargas, E. Sosa, M. Mercado, Clinical and biochemical characteristics of acromegalic patients with different abnormalities in glucose metabolism. Pituitary 14(3), 231–235 (2011)
C. Jonas, D. Maiter, O. Alexopoulou, Evolution of glucose tolerance after treatment of acromegaly: a study in 57 patients. Horm. Metab. Res. 48(5), 299–305 (2016)
B. Gonzalez, G. Vargas, A.L.E. de Los Monteros, V. Mendoza, M. Mercado, Persistence of diabetes and hypertension after multimodal treatment of acromegaly. J. Clin. Endocrinol. Metab. 103(6), 2369–2375 (2018)
Acknowledgements
This work was supported by the National Natural Science Foundation of China (Grant numbers 81602191, 81702467), the Shanghai Municipal Commission of Health and Family Planning (Grant number XYQ201640058), and the Shanghai Sailing Program (Grant number 17YF1401500).
Funding
This study was funded by the National Natural Science Foundation of China (Grant numbers 81602191, 81702467), the Shanghai Municipal Commission of Health and Family Planning (Grant number XYQ201640058), and the Shanghai Sailing Program (Grant number 17YF1401500).
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Ethical approval
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Informed consent
Informed consent was obtained from all individual participants included in the study.
Rights and permissions
About this article
Cite this article
He, W., Yan, L., Wang, M. et al. Surgical outcomes and predictors of glucose metabolism alterations for growth hormone-secreting pituitary adenomas: a hospital-based study of 151 cases. Endocrine 63, 27–35 (2019). https://doi.org/10.1007/s12020-018-1745-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12020-018-1745-7